Peptide News & Updates
Where we track FDA approvals, clinical trial results, and regulatory changes affecting therapeutic peptides. No press-release rewrites, no hype. Just the numbers, the timelines, and what they actually mean for patients and clinicians.
Regulatory
FDA Peptide Reclassification 2026: What's Changing for BPC-157, TB-500 and More
The Feb 27 announcement signals that roughly 14 peptides banned from compounding in 2023 may be restored to Category 1. Here is what it means and what is still missing.
Read moreFDA Approval
Oral Wegovy Launches in 2026: $149/Month Price and What It Means
Novo Nordisk launched the first oral GLP-1 for weight loss in January with a $149 cash price on NovoCare. A look at efficacy, pricing tiers, and the orforglipron race.
Read moreClinical Trial
Retatrutide Phase 3 TRIUMPH-4: 28.7% Weight Loss in 68 Weeks
Eli Lilly's triple agonist posted the largest weight-loss numbers ever seen in a Phase 3 obesity trial, but a new dysesthesia signal and a 2027 timeline complicate the picture.
Read moreMedical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.